Edition:
United States

PTC Therapeutics Inc (PTCT.OQ)

PTCT.OQ on NASDAQ Stock Exchange Global Select Market

17.72USD
21 Aug 2017
Change (% chg)

-- (--)
Prev Close
$17.72
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
258,901
52-wk High
$21.77
52-wk Low
$4.03

PTCT.OQ

Chart for PTCT.OQ

About

PTC Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of medicines using its expertise in ribonucleic acid (RNA) biology. Its product pipeline includes Ataluren (Translarna), PTC596 and RG7916. Its product candidate, ataluren, is an orally administered... (more)

Overall

Beta: 1.47
Market Cap(Mil.): $733.41
Shares Outstanding(Mil.): 41.39
Dividend: --
Yield (%): --

Financials

  PTCT.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -3.10 -- --
ROI: -37.56 2.83 14.89
ROE: -64.70 5.09 16.13

BRIEF-PTC Therapeutics qtrly loss per share $0.44

* Ptc therapeutics - qtrly total revenues $48 million versus $15.6 million; qtrly loss per share $0.44; sees fy translarna net sales $120 million - $140 million ‍​

Aug 08 2017

BRIEF-Great Point Partners Llc reports 5.24 percent passive stake in PTC Therapeutics Inc

* Great Point Partners LLC reports 5.24 percent passive stake in PTC Therapeutics Inc as of June 6, 2017 Source text: (http://bit.ly/2rAlBWB) Further company coverage:

Jun 16 2017

BRIEF-PTC Therapeutics announces FDA advisory committee meeting for Ataluren for treatment of nonsense mutation dystrophinopathy

* PTC Therapeutics announces FDA advisory committee meeting for Ataluren for the treatment of nonsense mutation dystrophinopathy

Jun 06 2017

BRIEF-PTC Therapeutics appoints Marcio Souza as chief operating officer

* ‍Appointments of Marcio Souza to chief operating officer and Christine Utter to principal financial officer and treasurer​ Source text for Eikon: Further company coverage:

Jun 05 2017

BRIEF-PTC enters into credit and security agreement for senior secured term loan facility

* Ptc therapeutics inc- on may 5, entered into a credit and security agreement for a senior secured term loan facility of $60.0 million - sec filing

May 08 2017

BRIEF-PTC Therapeutics qtrly loss per share $0.85

* PTC Therapeutics Inc - translarna net sales for 2017 are now anticipated to be between $115 and $130 million

May 08 2017

BRIEF-Complete Pharma reports 16.2 pct passive stake in PTC Therapeutics

* Complete Pharma Holdings II LLC reports 16.2 percent passive stake in PTC Therapeutics Inc as on April 20, 2017 - SEC filing Source: (http://bit.ly/2oBDGlC) Further company coverage:

Apr 27 2017

PRESS DIGEST - Wall Street Journal - March 17

March 17 The following are the top stories in the Wall Street Journal. Reuters has not verified these stories and does not vouch for their accuracy.

Mar 17 2017

PTC Therapeutics to buy expensive DMD drug, signals price change

PTC Therapeutics Inc said on Thursday it would buy Marathon Pharmaceuticals LLC's recently-approved Duchenne muscular dystrophy (DMD) drug, Emflaza, and promised to re-examine the hefty U.S. price tag for the treatment.

Mar 16 2017

UPDATE 3-PTC Therapeutics to buy expensive DMD drug, signals price change

* Even at lower price, Emflaza could still benefit PTC - analyst

Mar 16 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $32.76 +0.09
Merck & Co., Inc. (MRK.N) $61.97 +0.48
Bayer AG (BAYGn.DE) €107.25 +0.85
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates